Alembic Pharmaceuticals has received USFDA tentative approval for its generic Darolutamide tablets used in prostate cancer treatment. The approval applies to the 300 mg strength, positioning Alembic’s product as a generic equivalent to Nubeqa Tablets. With significant demand expected for this category, the company could gain momentum as it moves toward final commercialization.
Agilent Technologies is partnering with Veeda Lifesciences to launch a joint Center of Excellence in Bengaluru focused on regulatory-aligned analytical and bioanalytical workflows. The hub aims to produce consistent, inspection-ready data across early development, clinical and manufacturing stages, with special emphasis on GLP-1 peptides where sensitivity, throughput and data integrity are crucial. The collaboration combines Agilent mass spectrometry with Veeda proteomics and impurity analysis capabilities.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Agilent Technologies has expanded its collaboration with C-CAMP to broaden India’s access to advanced, high-resolution analytical and mass spectrometry platforms. The shared-infrastructure model lets startups, academia, and industry use specialized workflows for tasks like biotherapeutic characterization and quantitative biomolecular analysis—reducing the need for large upfront capital investments while supporting more reproducible translational research.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
